American Journal of Clinical Oncology-Cancer Clinical Trials最新文献

{"title":"Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.","authors":"Adeena Musheer, Muhammad S Mannan, Muhammad W Khan, Ayesha Junaid, Tuba Basit, Ali Shan Hafeez, Moazzam Shahzad","doi":"10.1097/COC.0000000000001361","DOIUrl":"10.1097/COC.0000000000001361","url":null,"abstract":"<p><strong>Objectives: </strong>Durvalumab consolidation following concurrent chemoradiotherapy (CRT) has become the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, survival outcomes reported in clinical trials and real-world studies have been inconsistent, making it difficult to understand the efficacy and safety of this treatment modality fully. Our study aims to pool the available evidence to evaluate the impact of durvalumab in patients with unresectable stage III NSCLC.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, and Web of Science were searched for studies including randomized controlled trials and real-world observational studies that assess durvalumab after definitive CRT in unresectable stage III NSCLC, till January 2026. Data extracted included median overall survival (OS), median progression-free survival (PFS), and survival rates. Random-effects meta-analyses were performed to pool OS and PFS.</p><p><strong>Results: </strong>A total of 3 studies comprising 861 patients with unresectable stage III NSCLC were included. Durvalumab consolidation after definitive CRT showed no statistically significant effect on OS (HR: 1.06, 95% CI: 0.52-2.14; I ²=51.6%; P =0.1268) or PFS (HR: 0.87, 95% CI: 0.45-1.68; I ²=49.6%; P =0.1374). Heterogeneity was moderate for both outcomes. In addition to these primary outcomes, multiple secondary efficacy and safety outcomes were systematically evaluated, including overall response rate and treatment-related adverse effects.</p><p><strong>Conclusions: </strong>Durvalumab consolidation demonstrates a favorable safety profile, but outcomes remain variable across studies. These findings highlight the importance of biomarker-driven patient selection and prospective real-world evaluation to maximize the clinical benefit of durvalumab in unresectable stage III NSCLC.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Adverse Events in Patients Receiving Platinum Analog-Based Chemotherapy.","authors":"Varun Vemulapalli, Carolina C Cruz, Maria J M N Santos, Rachel Mortan, Nina Quirk, Humberto R Nieves Jimenez, Andrew Sullivan, Anirudha Chatterjee, Jacob Reitnauer, Cristina Natha, Anusha Thomas, Lavanya Viswanathan, Van K Morris, David Richards, Karen C Kim, Yinghong Wang","doi":"10.1097/COC.0000000000001358","DOIUrl":"https://doi.org/10.1097/COC.0000000000001358","url":null,"abstract":"<p><strong>Objectives: </strong>Many patients with cancer receive chemotherapy alongside glucagon-like peptide-1 receptor agonists (GLP-1 RA) to manage type 2 diabetes or obesity. However, both GLP-1 RA and platinum-based chemotherapies can cause upper gastrointestinal (GI) adverse effects (AE) such as nausea and vomiting. This study aimed to evaluate the impact of GLP-1 RA use in patients receiving platinum-based chemotherapy, focusing on GI AE incidence, risk factors, and treatment outcomes.</p><p><strong>Methods: </strong>This single-center study retrospectively reviewed patients who were treated with a platinum-based therapy and concurrent GLP-1 RA and developed symptoms of upper GI AE.</p><p><strong>Results: </strong>The study included 200 patients. Upper GI adverse events occurred in 126 patients. Compared with patients without GI AE, patients with GI AE received fewer doses of platinum therapy (median: 2.5 vs. 5, P<0.0001) and had higher all-cause mortality (40.5% vs. 25.7%, P=0.034), shorter follow-up (median: 1.5 vs. 2.7 y, P<0.0001), and a higher rate of hypothyroidism (35.1% vs. 20.6%, P=0.025). GI AEs were treated with 5-HT3 receptor antagonists in 123 (99.2%) patients and corticosteroids in 5 (4.0%). GI AE symptoms lasted a median of 42.5 days; 92.7% achieved clinical remission of GI AE. Twenty-one (16.7%) patients required hospitalization for GI AE, of whom 4 required rehospitalization. Platinum analogs were discontinued in 72 (57.1%) patients and resumed in 57 (79.2%). GLP-1 RA was discontinued in 11 (8.7%) patients.</p><p><strong>Conclusions: </strong>Most patients receiving GLP-1 RA and platinum-based chemotherapy developed mild GI AE that responded to conservative management.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Distribution of Tenosynovial Giant Cell Tumor: Analysis of Surveillance, Epidemiology, and End Results Database.","authors":"Felicia Tejawinata, Malena Jhonson, Pingfu Fu, Ankit Mangla","doi":"10.1097/COC.0000000000001360","DOIUrl":"https://doi.org/10.1097/COC.0000000000001360","url":null,"abstract":"<p><strong>Objectives: </strong>Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal tumor driven by overexpression of colony-stimulating factor 1 (CSF1) in a few neoplastic synovial cells. Although known to be an ultrarare tumor, the racial distribution of TGCT is understudied.</p><p><strong>Methods: </strong>We queried the Surveillance, Epidemiology, and End Results (SEER) database versions 8 (1975 to 2021) and 22 (2000 to 2021) for patients with TGCT. Patients with TGCT were identified using ICD-O-3 codes 9252/0 (benign TGCT) and 9252/3 (malignant TGCT). Descriptive statistics for racial distribution, relative survival, and other parameters were conducted using the χ2 test.</p><p><strong>Results: </strong>A total of 78 patients with TGCT were identified in the SEER 22 database. Racial distribution was significantly in favor of White patients (n=51) versus Black patients (n=5) and Asian or Pacific Islander (AAPI) patients (n=5) (P<0.001). Twenty-two additional cases were identified in the SEER 8 database, with a higher preponderance among White patients (n=19) compared with Black patients (n=2) and AAPI patients (n=1) (P<0.001). In the SEER 22 and 8 data sets, the relative survival at 12 months was highest for White patients (98.5% and 90%, respectively), followed by AAPI patients (87.6% in both data sets), and then by Black patients (80% and 80.7%, respectively).</p><p><strong>Conclusion: </strong>TGCT has a significantly higher incidence in White patients compared with non-White patients. Relative survival appears favorable overall but may be better among White patients than among non-White patients.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigation and Care Coordination in Breast Cancer: Early Findings From a Phase I Clinical Trial.","authors":"Afua Ofori-Darko, Misty Walker, Ursula J Burnette, Shearwood McClelland","doi":"10.1097/COC.0000000000001357","DOIUrl":"10.1097/COC.0000000000001357","url":null,"abstract":"<p><strong>Objective: </strong>To examine the impact of patient navigation on care coordination, health care access, appointment adherence, psychosocial outcomes, and equity among patients with breast cancer enrolled in the Navigator-Assisted Hypofractionation (NAVAH) trial.</p><p><strong>Methods: </strong>This prospective comparative analysis used pre- and postradiotherapy (RT) survey data from an ongoing multicenter phase I trial. The pre-RT cohort included 44 patients; post-RT analyses compared 14 patients who electively received navigation with 13 who did not. The cohort was predominantly low-income, with 89% reporting annual household income below $50,000.</p><p><strong>Results: </strong>At baseline, the mean pre-RT composite score was 31.1, with transportation challenges and mixed perceptions of equitable care commonly reported. Post-RT, navigated patients reported more favorable accessibility, accommodation, and acceptability scores than nonnavigated patients, while affordability scores were similar. Complete appointment attendance was 92% with navigation versus 83% without navigation.</p><p><strong>Conclusions: </strong>Patient navigation was associated with more favorable health care access experiences, though adherence differences were not statistically significant.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-Enabled Early Detection of Chemo-Induced Cardiotoxicity Patterns Using ECG Time Series Data: A Simulated Oncology Framework.","authors":"Kamal Upreti, Jossy P George, Khushboo Malik, G V Radhakrishnan, Agnieszka Góra-Błaszczykowska","doi":"10.1097/COC.0000000000001280","DOIUrl":"10.1097/COC.0000000000001280","url":null,"abstract":"<p><strong>Objectives: </strong>Chemotherapy-induced cardiotoxicity is still a major clinical problem, usually appearing subclinically before structural or symptomatic cardiac dysfunction appears. Standard surveillance methods use imaging and biomarkers, which are time-intensive and money-intensive and can only identify damage at more advanced levels. Electrocardiography (ECG) provides a low-cost, non-invasive method that can detect early electrophysiological changes but is not fully utilized in cardio-oncology. The present work was designed to build an explainable machine learning model for predicting chemo-like cardiotoxicity patterns at an early stage from single-lead ECG signals.</p><p><strong>Methods: </strong>A public ECG data set (n=4997 segments) underwent preprocessing and was converted to 18 temporal, morphologic, and spectral features. Two ensemble learning algorithms-Random Forest and XGBoost-were trained and validated with stratified splits. Model performance was assessed with ROC-AUC, PR-AUC, and F1-score with 1000 bootstrap resampling. Feature interpretability was evaluated through permutation importance and SHAP analysis.</p><p><strong>Results: </strong>Both models scored near-perfect classification (ROC-AUC and PR-AUC>0.99, F1-score ≈ 0.986). Spectral entropy, band3 (high-energy frequency), QT surrogate, and peak count were the top features ranking alongside early cardiotoxicity indicators like repolarization instability and autonomic imbalance.</p><p><strong>Conclusions: </strong>The feature-driven, interpretable ML architecture suggested here shows that single-lead ECG has the potential to be an affordable and clinically relevant tool for the early detection of chemotherapy-induced cardiotoxicity. The method provides a feasible route toward implementation in precision cardio-oncology, particularly in resource-poor or ambulatory environments.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"383-389"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard-of-Care Treatment of Glioblastoma: Out-of-Pocket Cost Modeling of Adjuvant Radiation Therapy Duration Across Current-Year Medicaid and Medicare Plans.","authors":"Ena C Oboh, Victoria S Wu, Martha Khlopin, Shearwood McClelland","doi":"10.1097/COC.0000000000001324","DOIUrl":"10.1097/COC.0000000000001324","url":null,"abstract":"<p><strong>Objectives: </strong>The optimal radiotherapy (RT) duration for older adults with glioblastoma (GBM)-6 weeks (60 Gy/30 fractions) versus 3 weeks (40 Gy/15 fractions)-remains debated. Level 1 evidence demonstrates no significant difference in survival between these regimens. Limited data exist on how insurance coverage influences patient out-of-pocket (OOP) costs across treatment lengths. This study quantifies OOP expenses by insurance plan to improve cost transparency and inform decision-making.</p><p><strong>Methods: </strong>Using NCCN guidelines, standard treatment protocols were defined, including surgical resection, adjuvant RT, and concurrent and adjuvant temozolomide for 12 cycles. A 2-year cost model was constructed for a Medicare- and/or Medicaid-eligible patient aged 65 years or older with GBM. Aggregate OOP costs were calculated by summing deductibles, copayments, and coinsurance under Medicaid, Original Medicare, Medigap Plan G, and Medicare Part D.</p><p><strong>Results: </strong>Treatment charges included neurosurgery, neuro-oncology, and radiation oncology consultations; follow-up; diagnostic imaging; RT planning and delivery; systemic therapy; laboratory monitoring; and tumor-treating fields. Under Original Medicare, beneficiaries pay 20% of Medicare Part B charges after the deductible, with no annual OOP cap, and prescription drug costs under Part D. OOP costs were higher for 30-fraction RT compared with 15-fraction RT. Medigap Plan G beneficiaries incurred OOP costs of $2332.04 and $2319.42 for 30- and 15-fraction RT, respectively. Medicaid fully covered all approved services.</p><p><strong>Conclusions: </strong>Three-week RT for GBM reduces patient OOP costs by ∼5% compared with 6-week RT. Incorporating financial considerations into treatment discussions may help reduce the economic burden of GBM care and support shared decision-making.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"397-400"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of Palmitoylation-Related Genes in the Prognostic and Immunologic Characterization of Lung Adenocarcinoma.","authors":"Pingjing Li, Yun Xiong","doi":"10.1097/COC.0000000000001273","DOIUrl":"10.1097/COC.0000000000001273","url":null,"abstract":"<p><strong>Objectives: </strong>Lung adenocarcinoma (LUAD), which is the most frequently diagnosed form of lung cancer, constitutes a major global health challenge due to its significant mortality rate. Palmitoylation, as a key post-translational modification of proteins, plays an important role in tumor progression. However, its influence on sculpting the tumor immune microenvironment (TME) and its subsequent impact on patient prognosis remains incompletely understood.</p><p><strong>Methods: </strong>This study was based on the TCGA-LUAD and GSE72094 cohort data sets to explore the potential role of palmitoylation-related genes (PRGs) in LUAD. Through the integration of differential analysis, weighted gene coexpression network analysis (WGCNA), univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) regression analysis, prognostic genes for LUAD were screened. Furthermore, the infiltration patterns of immune cells across different groups were assessed by applying the ssGSEA and CIBERSORT algorithms. To elucidate the potential biological processes mediated by PRGs in LUAD pathogenesis, GSEA, GO and KEGG enrichment analyses, were used. In addition, the consensus clustering method was utilized for identify molecular subtypes of LUAD.</p><p><strong>Results: </strong>This study identified 5 PRGs as prognostic genes for LUAD and constructed a robust prognostic model. Immune infiltration analysis indicated that the level of immune cell infiltration in patients of the high-risk group was significantly lower. Further enrichment analysis showed that the upregulated differentially expressed genes (DEGs) in the high and low risk groups were related to the cytoskeleton, while the downregulated DEGs were related to lipid metabolism. In addition, this study successfully classified LUAD into 2 molecular subtypes with significant differences.</p><p><strong>Conclusions: </strong>Our research delves into the intricate TME and molecular mechanisms of LUAD, providing new insights into the pathologic mechanism and treatment strategies of LUAD.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"361-371"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145670777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Interruptions in Chemotherapy on Survival for Patients With Metastatic or Recurrent Cervical Cancer.","authors":"Risha Sinha, Arianna Portmann-Baracco, April R Gorman, Elizabeth C Stock, Steven Blaine Holloway, David S Miller, Jayanthi S Lea","doi":"10.1097/COC.0000000000001279","DOIUrl":"10.1097/COC.0000000000001279","url":null,"abstract":"<p><strong>Objectives: </strong>Chemotherapy interruptions are a frequent event during treatment of solid tumors and have been associated with adverse survival outcomes. Our objective was to determine the impact of intercycle delay during first-line systemic chemotherapy on survival in patients with metastatic (stage IVB) or recurrent cervical cancer.</p><p><strong>Methods: </strong>A retrospective cohort study identified patients with metastatic or recurrent cervical cancer treated at our institutions. Demographics, clinicopathologic information, first-line chemotherapy regimens with associated intercycle delays, and outcome measures were abstracted from medical records. Delays were categorized as modifiable (social determinants of health, logistics, treatment break) or nonmodifiable (cytopenias, organ dysfunction, chemotherapy reaction, infection, ECOG status). Data were analyzed using descriptive statistics, Kaplan-Meier survival estimate, and log-rank tests to calculate significance ( P <0.05).</p><p><strong>Results: </strong>Two hundred ten patients were evaluable for this study. 178 (85%) had at least one intercycle delay. One thousand eight hundred seventy-three chemotherapy cycles were completed with 701 (37%) delays. There was an equal proportion of modifiable (352/701) and nonmodifiable (349/701) delays. Patients with one or more intercycle delay had a longer median PFS (13 mo, IQR: 7 to 24) compared with those without delays (8 mo, IQR: 4 to 17), P =0.042. PFS stratified by subgroups revealed patients with modifiable delays as having improved PFS ( P =0.036) and nonmodifiable subgroup trending towards improved PFS ( P =0.058) compared with patients with no delays. There was no PFS difference between the modifiable and nonmodifiable subgroups and no overall survival differences.</p><p><strong>Conclusions: </strong>Intercycle delays during first-line systemic chemotherapy for metastatic or recurrent cervical cancer do not have an adverse effect on survival.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"390-396"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Model Based On Neutrophil-Related Genes Constructs to Assess Prognosis and Immune Landscape in Diffuse Large B-Cell Lymphoma.","authors":"Xinfang Gao, Xinguo Luo, Hongwei Ye, Shanshan Hu, Fangquan Yu, Panpan Xu, Fangjing Shi, Li Huang","doi":"10.1097/COC.0000000000001272","DOIUrl":"10.1097/COC.0000000000001272","url":null,"abstract":"<p><strong>Objectives: </strong>Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, represents a highly heterogeneous cancer. Neutrophils, as the core effector cells of intrinsic immunity, play an important role in regulating the tumor microenvironment (TME) due to their functional complexity. This study aimed to assess the prognostic significance of neutrophil-related genes (NRGs) in DLBCL and their association with the TME.</p><p><strong>Methods: </strong>Transcriptomic data and clinical information of DLBCL patients were retrieved from TCGA and GEO databases. Characterized genes were screened by LASSO, random forest, and XGBoost algorithm. A prognostic model was constructed by multivariate Cox regression analysis, and the predictive efficacy of the accuracy of the model was assessed through receiver operating characteristic (ROC) curves and Kaplan-Meier (K-M) survival analysis. Subsequently, immune cell infiltration, gene enrichment, tumor mutation burden (TMB), and drug sensitivity were analyzed across different risk groups. Finally, consensus clustering was used to identify molecular subtypes of DLBCL, and immune cell activity and immune function differences among these subtypes were compared through immune infiltration analysis.</p><p><strong>Results: </strong>A risk stratification model established based on NRGs (TGFB2, LAMA4, GGH, F5, CD163, RasGRP4, ANXA2, S100A4, and PTEN) significantly differentiated the survival prognosis of patients in the high and low-risk groups. The low-risk group was found to have elevated immunoreactivity and a higher ESTIMATE composite score, according to immune infiltration analysis. Enrichment analysis revealed that the high risk exhibited upregulation of cell cycle regulation, DNA repair and chromosome dynamics pathways, while the low risk group exhibited extracellular matrix remodeling and activation of cytokine signaling pathways.</p><p><strong>Conclusions: </strong>The NRG-based risk model can effectively predict the survival outcomes and immune profiles of DLBCL patients, offering a novel perspective on the link between NRGs and DLBCL.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"372-382"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145642565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Navigation for Cancer Care in Sub-Saharan Africa: A Scoping Review.","authors":"Elizabeth O Olatunji, Benjamin K Talom, Ena C Oboh, Shearwood McClelland","doi":"10.1097/COC.0000000000001268","DOIUrl":"10.1097/COC.0000000000001268","url":null,"abstract":"<p><p>Cancer is a major health threat in sub-Saharan Africa (SSA). Patient navigation has emerged as a strategy to address this, but the scope and impact of patient navigation for cancer care in SSA remains unclear. We aimed to comprehensively map the existing literature on patient navigation interventions for cancer care in SSA. A scoping review was conducted using a standardized 3-step search strategy. Eligible studies involved a patient navigation intervention for cancer care in SSA. Data were extracted on study, participant and navigator characteristics, intervention outcomes and implementation barriers and facilitators. Twenty-two studies describing 20 distinct interventions across 10 countries were included. Most studies were descriptive, focused on breast and cervical cancers and targeted the treatment stage of care. Navigator roles included patient education, psychosocial support, care coordination, and attenuation of patient barriers to care. Patient navigation appeared feasible, acceptable, and beneficial across a variety of study populations in this setting, but limited funding was a commonly reported barrier to maintenance. Cancer patient navigation is a promising strategy to improve cancer outcomes in SSA. Strategic investment is needed to support sustainable scale-up and maximize the impact of cancer patient navigation in the region.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":"401-411"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}